<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7927838</article-id><article-id pub-id-type="pmcid-ver">PMC7927838.1</article-id><article-id pub-id-type="pmcaid">7927838</article-id><article-id pub-id-type="pmcaiid">7927838</article-id><article-id pub-id-type="pmid">33106267</article-id><article-id pub-id-type="doi">10.1128/AAC.01804-20</article-id><article-id pub-id-type="publisher-id">01804-20</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant <named-content content-type="genus-species">Escherichia coli</named-content> Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice</article-title><alt-title alt-title-type="running-head">Ciprofloxacin PKPD in Experimental UTI</alt-title><alt-title alt-title-type="short-authors">Jakobsen et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jakobsen</surname><given-names initials="L">Lotte</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lundberg</surname><given-names initials="CV">Carina Vingsbro</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1966-8302</contrib-id><name name-style="western"><surname>Frimodt-M&#248;ller</surname><given-names initials="N">Niels</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><aff id="aff1"><label>a</label><addr-line>Bacteria, Parasites &amp; Fungi, Statens Serum Institut, Copenhagen, Denmark</addr-line></aff><aff id="aff2"><label>b</label><addr-line>Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Niels Frimodt-M&#248;ller, <email>niels.frimodt-moeller@regionh.dk</email>.</corresp><fn id="fn1" fn-type="present-address"><label>*</label><p>Present address: Lotte Jakobsen, ALK-Abell&#243;, H&#248;rsholm, Denmark.</p></fn><fn fn-type="other"><p><bold>Citation</bold> Jakobsen L, Lundberg CV, Frimodt-M&#248;ller N. 2021. Ciprofloxacin pharmacokinetics/pharmacodynamics against susceptible and low-level resistant <italic toggle="yes">Escherichia coli</italic> isolates in an experimental ascending urinary tract infection model in mice. Antimicrob Agents Chemother 65:e01804-20. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.01804-20">https://doi.org/10.1128/AAC.01804-20</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>26</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2021</year></pub-date><volume>65</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">376542</issue-id><elocation-id>e01804-20</elocation-id><history><date date-type="received"><day>21</day><month>8</month><year>2020</year></date><date date-type="rev-request"><day>26</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>06</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>16</day><month>06</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-06-16 00:16:32.257"><day>16</day><month>06</month><year>2021</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020 American Society for Microbiology.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Society for Microbiology</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="asm" xlink:href="https://doi.org/10.1128/ASMCopyrightv2"><license-p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/ASMCopyrightv2">All Rights Reserved</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AAC.01804-20.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="AAC.01804-20.pdf"/><abstract abstract-type="precis"><p>The mouse ascending urinary tract infection model was used to study the pharmacokinetic/pharmacodynamic (PKPD) relationships of the effect of ciprofloxacin in subcutaneous treatment for 3 days with varying doses and dosing intervals against a susceptible <named-content content-type="genus-species">Escherichia coli</named-content> strain (MIC, 0.032&#8201;mg/liter). Further, a humanized dose of ciprofloxacin was administered for 3 days against three <named-content content-type="genus-species">E. coli</named-content> strains with low-level resistance, i.e., MICs of 0.06, 0.25, and 1&#8201;mg/liter, respectively.</p></abstract><abstract><title>ABSTRACT</title><p>The mouse ascending urinary tract infection model was used to study the pharmacokinetic/pharmacodynamic (PKPD) relationships of the effect of ciprofloxacin in subcutaneous treatment for 3 days with varying doses and dosing intervals against a susceptible <named-content content-type="genus-species">Escherichia coli</named-content> strain (MIC, 0.032&#8201;mg/liter). Further, a humanized dose of ciprofloxacin was administered for 3 days against three <named-content content-type="genus-species">E. coli</named-content> strains with low-level resistance, i.e., MICs of 0.06, 0.25, and 1&#8201;mg/liter, respectively. Against the susceptible isolate, ciprofloxacin was highly effective in clearing the urine with daily doses from 10&#8201;mg/kg, but the dosing regimen had to be divided into at least two doses for optimal effect. Ciprofloxacin could not clear the urine or kidneys for the low-level-resistant strains. PKPD correlations with all strains combined showed that for the AUC<sub>24</sub>/MIC there was a slightly higher correlation with effect in urine and kidneys (<italic toggle="yes">R</italic><sup>2</sup>, 0.71 and 0.69, respectively) than the %T<sub>&gt;MIC</sub> (<italic toggle="yes">R</italic><sup>2</sup>, 0.41 and 0.61, respectively). Equal correlations for the two PKPD indices were found for reduction of colony counts (CFU) in the bladder tissue, but not even the highest dose of 28&#8201;mg/kg &#215; 6 could clear the bladder tissue. In conclusion, ciprofloxacin is highly effective in clearing the urine and kidney tissue for fully susceptible <named-content content-type="genus-species">E. coli</named-content>, while even low-level resistance in <named-content content-type="genus-species">E. coli</named-content> obscures this effect. While the effect of ciprofloxacin is mostly AUC/MIC driven against <named-content content-type="genus-species">E. coli</named-content> infection in the urinary tract, the effect in urine depends on the presence of ciprofloxacin in the urine during most of a 24-h period.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>urinary tract infection</kwd><kwd><italic toggle="yes">E. coli</italic></kwd><kwd>ciprofloxacin</kwd><kwd>PKPD</kwd><kwd>ciprofloxacin resistance</kwd><kwd><italic toggle="yes">Escherichia coli</italic></kwd><kwd>experimental mouse model</kwd></kwd-group><funding-group><award-group id="award1"><funding-source><institution-wrap><institution>Ministry of Science, Innovation and Higher Education | Danish Agency for Science and Higher Education (Danish Agency for Science, Technology and Innovation)</institution><institution-id>https://doi.org/10.13039/501100001825</institution-id></institution-wrap></funding-source><award-id>09-067075/DSF</award-id><award-id>7044-00001B</award-id><principal-award-recipient><name name-style="western"><surname>Frimodt-M&#248;ller</surname><given-names>Niels</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><fig-count count="3"/><table-count count="3"/><equation-count count="0"/><ref-count count="30"/><page-count count="10"/><word-count count="5866"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2021</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>